Navigation for Antimicrobial Resources

Daptomycin

Please note: This is for information only.

Refer to local guidelines for treatment recommendations


 

  • A cyclic lipopeptide active against Gram positive bacteria only
  • Bactericidal
  • Not absorbed therefore for IV use only
  • Dose on actual body weight
  • Reduce dose if CrCl<30ml/min - see Dose Adjustment for Renal Impairment

Patient weight (actual)

Daptomycin dose

<45kg

6mg/kg iv od

46-60kg

350mg iv od

61-85kg

500mg iv od

86-115kg

700mg iv od

116-140kg

850mg iv od

>140kg

Discuss with Microbiology

  • Plasma CPK should be measured at baseline and at regular intervals (at least once weekly) during therapy in all patients
  • CPK should be measured more frequently (e.g. every 2-3 days at least during the first two weeks of treatment) in patients who are at higher risk of developing myopathy. For example, patients with any degree of renal impairment (creatinine clearance < 80 ml/min), including those on haemodialysis or CAPD, and patients taking other medicinal products known to be associated with myopathy (e.g. HMG-CoA reductase inhibitors, fibrates and ciclosporin).
  • Discontinue in the presence of unexplained muscle symptoms if the CPK level reaches greater than 5 times upper limit of normal

Main indications:

  • Complicated skin and soft-tissue infections (cSSTI).
  • Right-sided infective endocarditis (RIE) due to Staphylococcus aureus
  • Staphylococcus aureus bacteraemia when associated with RIE or with cSSTI
  • Orthopaedic infections on Consultant Microbiologist advice (unlicenced indication)

Active against most strains of:

  • Staphylococcus
  • Streptococcus
  • Clostridium perfringens
  • Peptostreptococcus

Inherently resistant to:

  • Gram negative organisms